Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus– and Hepatitis C Virus–Related Hepatocellular Carcinoma
Daniel Q. Huang, Joseph Hoang, Rubayet Kamal, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 7, pp. 790-799
Closed Access | Times Cited: 18

Showing 18 citing articles:

Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions
Lung‐Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 12, pp. 834-851
Closed Access | Times Cited: 29
Adjuvant therapy for hepatocellular carcinoma: Dilemmas at the start of a new era
Jian‐Hong Zhong
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 806-810
Open Access | Times Cited: 6
Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV‐related hepatocellular carcinoma undergoing radiofrequency ablation
Kuo‐Cheng Wu, I‐Cheng Lee, Chen‐Ta Chi, et al.
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 7, pp. 940-952
Open Access | Times Cited: 4
Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040
Sikai Qiu, Jiangying Cai, Zhangjie Yang, et al.
JAMA Network Open (2024) Vol. 7, Iss. 11, pp. e2445525-e2445525
Open Access | Times Cited: 4
Arginine tagged liposomal carrier for the delivery of celastrol for ferroptosis-induced hepatocellular carcinoma therapy
Man-Man Qi, Kai Zhang, Xue Zhang, et al.
Colloids and Surfaces B Biointerfaces (2025) Vol. 250, pp. 114546-114546
Closed Access
Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: a ten-year retrospective cohort study
Jian Liu, Shilei Bai, Xintong Shi, et al.
European Journal of Surgical Oncology (2025) Vol. 51, Iss. 5, pp. 109621-109621
Closed Access
Where Is the Future of Adjuvant Therapy for Hepatocellular Carcinoma?
Yizhen Fu, Yaojun Zhang, Dandan Hu, et al.
Journal of Clinical Oncology (2025)
Closed Access
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
Yu Shi, Nicholas Chien, Ashley Fong, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Direct-acting antivirals lower mortality and recurrence in HCV-related hepatocellular carcinoma post liver resection: A multicenter international study
Woo Jin Choi, Tommy Ivanics, Marco P. A. W. Claasen, et al.
Surgery (2025) Vol. 183, pp. 109396-109396
Open Access
Targeting Hepatic Cancer Stem Cells (CSCs) and Related Drug Resistance by Small Interfering RNA (siRNA)
Saade Abdalkareem Jasim, Omar Dheyauldeen Salahdin, H. Malathi, et al.
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 4, pp. 3031-3051
Closed Access | Times Cited: 2
Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease
Yen Thi-Hai Pham, Daniel Q. Huang, Zhongjie Zhang, et al.
European Journal of Cancer Prevention (2024)
Closed Access | Times Cited: 1
Optimizing care of HBV infection and HBV-related HCC
Shi Yan Lee, Benjamin Nah, Jazleen Leo, et al.
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access
Hepatozelluläres Karzinom: Effekte der antiviralen Behandlung

Zeitschrift für Gastroenterologie (2024) Vol. 62, Iss. 08, pp. 1188-1189
Closed Access
Timing of antiviral therapy in patients with hepatitis B virus related hepatocellular carcinoma undergoing hepatectomy
Dong-Ling Wan, Liqi Sun
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 9, pp. 1251-1255
Open Access
Role of galectin-3 in enhancing HBV replication and predicting hepatocellular carcinoma: mechanistic insights and clinical implications
Wei Jiang, Qingmin Zeng, Dongbo Wu, et al.
Research Square (Research Square) (2024)
Closed Access
Hepatozelluläres Karzinom: Effekte der antiviralen Behandlung

TumorDiagnostik & Therapie (2024) Vol. 45, Iss. 08, pp. 504-504
Closed Access
Sex differences in hepatocellular carcinoma
James Ho, Prem Harichander Thurairajah, Jazleen Leo, et al.
Hepatoma Research (2024)
Open Access
Reply: Is the evidence convincing for the expansion of CHB treatment criteria to reduce the risk of HCC?
Daniel Q. Huang, Mindie H. Nguyen
Hepatology (2024) Vol. 80, Iss. 3, pp. E39-E39
Open Access
Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: a ten-year cohort study
Jian Liu, Jianbo Lin, Xintong Shi, et al.
Research Square (Research Square) (2024)
Open Access
Page 1

Scroll to top